This inventor holds 3 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignees: Nexgenix Pharmaceuticals, Inc., Universitéde Strasbourg. Active years: 2012-2013.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2012-2013
Title: Ruihong Chen: Innovator in Neurofibroma Treatment
Introduction
Ruihong Chen is a notable inventor based in Foster City, CA (US). He has made significant contributions to the field of medical treatments, particularly focusing on neurofibromas. With a total of 3 patents, his work has the potential to impact many lives.
Latest Patents
Chen's latest patents include innovative methods for treating neurofibromas. One patent describes a method for locally treating neurofibromas, such as dermal and subdermal types, by applying a composition either topically or intralesionally. This method specifically avoids systemic administration, ensuring targeted treatment. Another patent focuses on the treatment of neurofibromatosis using radicicol and its derivatives. This invention outlines compounds and methods for treating NF2-deficient or NF1-deficient cells, as well as neurodegenerative diseases. It also includes strategies for inhibiting the growth of tumors associated with these deficiencies.
Career Highlights
Throughout his career, Ruihong Chen has worked with various organizations, including Nexgenix Pharmaceuticals, Inc. and Université de Strasbourg. His experience in these institutions has contributed to his expertise in developing innovative treatments.
Collaborations
Chen has collaborated with notable individuals in his field, including Allan E Rubenstein and Jin-Chen Yu. These partnerships have likely enhanced his research and development efforts.
Conclusion
Ruihong Chen's work in the treatment of neurofibromas and neurofibromatosis showcases his dedication to medical innovation. His patents reflect a commitment to improving patient outcomes through targeted therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile